Oncophage vitespen: Additional Phase I/II data

Additional data from 32 evaluable patients with recurrent high-grade glioma in an open-label, U.S. Phase I/II trial showed that Oncophage resulted in an overall median survival of 44 weeks following tumor resection. Additionally, 70% and 41% of patients survived >36 weeks and >=1 year, respectively. Oncophage was well tolerated with no serious adverse events. The company plans to enroll about 50 patients in the trial. Data were presented at the Brain Tumor Research and Therapy meeting in Travemuende. ...